Abstract
INTRODUCTION
Colorectal cancer (CRC) is a common malignant tumor [1] [2] . In 2016, the incidence and mortality in the United States were respectively ranked fourth and second [3] [4] [5] [6] [7] . In 2015, 376000 patients were newly diagnosed with CRC in China and 191000 patients died from the disease [8] . Surgical resection remains the mainstay of treatment for local and regional disease [9] [10] [11] [12] [13] [14] . Adjuvant chemotherapy is frequently used in advanced colon cancer and CRC, but remains controversial for [15] [16] [17] [18] [19] [20] [21] . Understanding the pathologic staging in conjunction with prognostic values is essential to making therapeutic decisions. The American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging model has provided this universal modality since its first edition in 1977 [22] . Since then, the AJCC has repeatedly revised this guideline ( Figure 1 ) to continuously guide clinical treatment.
The eighth edition of the AJCC staging system (AJCC-8 th ) was released on October 6, 2016 in Chicago, IL, United States, and was implemented globally on January 1, 2018, which included significant changes for CRC patients with stage Ⅳ disease [23] . The Cancer Council under the American College of Surgeons required the use of the AJCC-8 th staging system as the "primary language"
for cancer reporting. In 2013, AJCC established the "Evidence-Based Medicine and Statistics Core Group" of the 8 th edition of the staging system. The organization is composed of clinical physicians, statisticians, and methodologists. It is responsible for determining the level of evidence for any updated content of the AJCC staging system. The level of evidence is divided into four levels, and the quality of evidence represented by it gradually decreases from level Ⅰ to level Ⅳ. Level Ⅰ requires that the evidence is from multiple large national or international studies, has consistent results, has good research requirement design and implementation, was conducted in appropriate patient populations with appropriate study endpoints and appropriate treatment options, either as prospective studies or review-based studies based on patient populations, but all studies must be methodologically assessed. Level Ⅱ requires that the evidence comes from at least one large study and had good design and implementation, was conducted in a suitable patient population with a suitable study endpoint, and has external reliability (generally the representative and extrapolated capabilities of the study are better). Level Ⅲ includes evidence from a study with certain flaws, defects in the number of possible subjects, size, or quality of the study, or the consistency of multiple findings, the appropriateness of the patient population, and the appropriateness of the results. Level Ⅳ includes evidence wherein no reasonable research had been done. Only evidence from levels Ⅰ-Ⅲ could be included in the 8th version of the staging system.
A major difference between AJCC-7 th , and AJCC-8 th is that the CRC staging system was revised to include a new stage involving peritoneal metastasis (named stage ⅣC) (see Tables 1 and 2 for details). Based on a variety of evidence-based medical evidence [24, 25] , the AJCC-8 th CRC staging system continues to recommend vascular lymphatic vessel infiltration and tumor deposition as prognostic level information, while microsatellite instability status and BRAF gene status are used as prognostic factors, and BRAF, KRAS, and degeneration of the NRAS gene were used as a predictor of efficacy (Table 3 ) [26] . The increased complexity of the AJCC-8 th staging model was intended to improve the prognostic staging of CRC, but the impact of these changes remains unclear. In this study, we used data from our institutional registries to compare the prognostic accuracy of criteria from AJCC-7 th and AJCC-8 th in patients with stage 0-Ⅳ through survival models. We also explored the relationship between positive node and tumor size, differentiation, tumor invasion, chemotherapy, tumor-node-metastasis (TNM) staging from AJCC-7 th , and TNM staging from AJCC-8 th . In addition, we also discussed the pathological importance of lymph invasion, vein invasion, and nerve invasion according to AJCC-8 th .
MATERIALS AND METHODS

Patients
A total of 2080 patients with pathologically confirmed stage 0-Ⅳ CRC between 2006 and 2012 were collected from our institutional database. Then the following inclusion and exclusion criteria were applied to this cohort: (1) on the basis of a colonoscopy, computed tomography, pathological diagnosis of CRC, in or outside the hospital diagnosis in our hospital; (2) patients undergoing colorectal surgery in our hospital (including radical surgery and non-radical surgery); (3) diagnosis as a recurrence of the primary tumor or as a result of the death of the primary tumor; (4) cases with complete and detailed clinical and pathological data; and (5) cases with complete follow-up data and accurate data. Exclusion criteria were: (1) a serious heart, brain, liver, or lung disease led to intolerant surgery; (2) the non-CRC factors that led to the death of the pathological interstitial tumor, neuronal tumor, lymphoma, melanoma and other nonadenocarcinoma in addition to other malignant tumors;
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Follow-up
Patients were routinely followed in the outpatient clinic 2 wk after surgery for 3 mo and every 3 mo for the first year, then every 6 mo for the second year and every year for the next 3 year. Follow-up data was complemented by phone contact as well as contact with written mail.
Ethics statement
This study was carried out in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committee of Huzhou Central Hospital.
Preliminary processing of data
Using the extent of disease codes, tumor invasion (T staging), lymph node positivity (N staging), tumor metastasis (M staging) status, CRC was staged based on the AJCC-7 th and AJCC-8 th (Table 4 ). The patients were divided into three groups (N0, N1, N2) by the number of positive lymph nodes. Clinicopathological data were analyzed between the three groups. Patient status was designated into three outcome categories for diseasefree survival (DFS): (1) death from CRC; (2) recurrence from CRC; or (3) alive at the last follow-up. Patient status was designated into two outcome categories for overall survival (OS): (1) death from CRC; or (2) alive at the last follow-up.
Statistical analysis
SPSS 21 (Chicago, IL, United States) was used for data analysis. Intergroup measurement data were analyzed using ANOVA analysis of variance and count data were analyzed using Cross-Tab χ 2 analysis.
The relationship between positive lymph node and tumor size, differentiation, tumor invasion, chemotherapy, and TNM staging from AJCC-7 th , and TNM staging from AJCC-8 th were analyzed by linear and automatic linear regression and the functional equations were established. Survival curves were generated using Kaplan-Meier estimates, and 5-year DFS and OS were compared using the Log-rank test. Kaplan-Meier was also used to calculate the survival rate of DFS and OS in each group. Afterwards, Cross-table was used to compare the DFS and OS survival rates of sub-periods between AJCC-7 th and AJCC-8 th groups, and a histogram was generated.
P-values less than 0.05 were considered statistically significant.
RESULTS
Lymph staging (N) and clinicopathologic characteristics
During the 6-year study period, 2080 patients with stage 0-Ⅳ CRC were identified but only 1090 met our inclusion criteria. , and TNM staging from AJCC-8 th were indicators of good fit and showed significance (P < 0.05). The fitting degree for TNM staging from AJCC-7 th was 61.3% (Figure 2A ), and the index that had a significant influence on positive lymph nodes was shown in Figure 2B . However, chemotherapy was not included in the predictive importance index ( Figure  2C ). The importance of TNM staging from AJCC-7 th was 77%, and the importance of tumor invasion was 19%, the importance of tumor size was 3%, the degree of tumor differentiation was 1%. Figure 2D showed significant parameters of each coding amount and constant coefficient. The fitness for TNM staging from AJCC-8 th was 63.3% ( Figure 3A) , and the indexes that had a significant influence on positive lymph nodes were shown in Figure 3B . Chemotherapy was also included in the predictive importance index ( Figure 3C ). The importance of TNM staging from AJCC-8 th was 72%, the importance of tumor invasion was 20%, the importance of chemotherapy was 4%, the importance of tumor size was 3%, the degree of tumor differentiation was 1%. DFS and OS showed a significant right shift for stage Ⅳ B and a significant left shift for stage ⅣC (P = 0.001 and P < 0.001, respectively). Details were shown in Table 6 November 10, 2018|Volume 9|Issue 7| 
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DISCUSSION
In 1977, AJCC established the first edition of the cancer staging system. Revision to the system have been made every 6-8 years and until recently it has been regarded as the most comprehensive tool for prognostic and predictive grouping of patients with colon cancer [24] . However, when AJCC-6 th was released in 2002 [27] , it elicited criticism because survival of patients with stage ⅢA colon cancer was superior to that of patients with stage ⅡB colon cancer [28] . In 2010, the AJCC cancer staging system was updated to the 7 th edition [22, 29] . This edition included both the refinement of the classic TNM "anatomic blood" diagnostic system, the increase in tumor regression scores, and the risk of prognoses and curative effects for circumferential resection margins.
Evaluation index
The problem with AJCC staging of CRC was initially attributed to inadequate lymph node (LN) assessment. Previous studies demonstrated that the number of examined LNs impacted survival [30] [31] [32] [33] [34] . Subsequent studies showed a strong correlation between outcomes and compliance with 12-LN minimum [35] [36] [37] [38] [39] . In our study, in addition to analyzing the distribution of LN numbers in different N stages, we also focused on the effect of positive LN numbers on lymphatic pathology, and established a linear function.
In recent years, researchers have recognized the importance of tumorigenesis and the role of nonanatomic markers in establishing the prognosis and anticipated response to therapy [40] [41] [42] [43] [44] [45] . Of these factors, the circumferential margin of the resected non-peritonealized surface of the specimen (CRM) is relevant for prognostic assessment of patients with tumors in the ascending and descending colon [46, 47] . Microsatellite instability, KRAS mutation and the 18q LOH have been shown to have clinical prognostic significance [48, 49] . These factors have not been incorporated into the staging system because it is not clear how they should be used to determine prognosis or the need for adjuvant chemotherapy. In 2013, AJCC established the "Evidence-Based Medicine and Statistics Core Group" of the eighth edition system, which was responsible for determining the level of evidence for any updated content of the AJCC staging system. New evidence had to reach an evidence quality level of Ⅰ-Ⅲ to be factored into the staging system for the eighth edition.
AJCC-8 th did not include any updates for tumor staging. The definition of TD and N1c in the N-stage was further interpreted as the presence of encouraging tumor nodules in the lymphatic drainage area of the primary tumor, and no lymph node, vessel, or nerve structure identified during the period. The presence of TD did not alter the T stage of the primary tumor, but if it was not accompanied by lymph node metastasis, the TDs would change N stage (from N0 to N1c). If there was combined lymph node metastasis, the number of TDs did not need to be counted in the number of positive lymph nodes.
The latest version reaffirmed the definition of lymphatic infiltrating vessels. Any vessel lesions with or without residual vascular walls could be identified as lymphocytic infiltrates in storage vessels and become a routine item in the pathology report of the American College of Pathology. Our institutional pathologist recognized this and described them in the report ( Figure 5 ). Vascular lymphatic infiltration could be subdivided into small vessel infiltration (lymphatic or venular infiltration, defined as "L" positive) and venous infiltration (a structure surrounded by tumor immersion and endothelial cells, which contain red blood cells coated with smooth muscle machinery was defined as "V" positive). At the same time, it was found that tumor immersion and nerve tissue were defined as infiltration around the nerve. Lymphatic infiltration and perineural invasion were both important prognostic factors [50] [51] [52] [53] [54] [55] [56] . th version of CRC more than one organ or site, or in the peritoneum). In AJCC-8 th , another stage was added to describe colorectal peritoneal metastases (whether or not with metastasis of other organ sites). This is called M1c, and M1a and M1b were redefined as metastasis limited to one organ or site (such as liver, lung, ovary, extra-nodal lymph nodes, etc.) and transition beyond one organ or site, but without peritoneal metastasis, respectively. The reason for the change is that although peritoneal metastasis occur in 1% to 4% of patients with CRC, the prognosis is far worse than that of M1a and M1b patients who have metastasis of substantial organs [57] [58] [59] [60] [61] . We reclassified our cohort according to the AJCC-8 th criteria. The results showed that the DFS and OS of the M1a stage remained unchanged, while that of the M1b stage improved, and that of the M1c stage decreased significantly. This demonstrated that the M stage refinement was necessary. This additional classification in the eighth edition will have a positive and far-reaching effect on cancer treatment that will promote the individualized diagnosis and treatment of CRC patients. However, further analysis with additional institutional databases is needed to confirm our findings.
In conclusion, the addition of a sub-stage to classify peritoneal metastasis separately from distant organ metastasis in the AJCC-8 th manual has shown that peritoneal metastasis has a worse prognosis than organ metastasis in our cohort.
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Research motivation
In China, there are still many hospital surgeons and physicians who still use the old version to guide clinical practice and are uneducated about the new AJCC-8 th classifications.
Research objectives
We analyzed our institution's CRC cohort to determine differences in the survival trends based on the diagnostic classifications between AJCC-8 th and the previous version.
Research methods
A total 1090 patients of 2080 CRC patients were included in the study. The data were classified by AJCC-7 th and AJCC-8 th standards. Five-year disease-free survival (DFS) and overall survival (OS) were compared.
Research results
Linear regression and automatic linear regression showed lymph node positive functional equations by TNM staging from AJCC-7 and TNM staging from AJCC-8 th . Neurological invasion, venous infiltration, lymphatic infiltration, and tumor deposition put forward stricter requirements for pathological examination. AJCC-8 th staging yielded a proportional decrease of ⅣB from 2.8% to 0.8% and a new staging of ⅣC to 2%. Log-rank test showed that DFS and OS survival time of patients with ⅣC vs ⅣB was significantly shorter (P = 0.012).
Research conclusions
The addition of a sub-stage to classify peritoneal metastasis separately from distant organ metastasis in the AJCC-8 th manual has shown that peritoneal metastasis has a worse prognosis than organ metastasis in our cohort. Considering many prognostic factors, individualized treatment is particularly important to improve the survival time of stage Ⅳ patients, especially ⅣC patients.
Research perspective
Further studies can be done to improve outcomes for peritoneal metastasis CRC patients. Further analysis of additional institutional databases is needed to confirm our findings.
